N-[3-[(2-quinolinyl)methoxy]phenyl]ethane sulfonamide | 111974-55-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[3-[(2-quinolinyl)methoxy]phenyl]ethane sulfonamide
• 英文别名: N-[3-(quinolin-2-ylmethoxy)phenyl]ethanesulfonamide
• CAS: 111974-55-1
• 化学式: C₁₈H₁₈N₂O₃S
• 分子量: 342.419
• InChiKey: PPCZVCVPFUKZBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  76.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  间硝基苯酚 在 platinum(IV) oxide 氢气 、 caesium carbonate 、 三乙胺 、 potassium iodide 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 为溶剂， 25.0 ℃ 、241.32 kPa 条件下， 反应 18.5h， 生成 N-[3-[(2-quinolinyl)methoxy]phenyl]ethane sulfonamide
  参考文献：
  名称：

  N-[(Arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene d4 antagonists of novel structure

  摘要：

  Two series of compounds, N-[(arylmethoxy)phenyl] sulfonamides and N-[(arylmethoxy)naphthyl] sulfonamides, were prepared as leukotriene D4 (LTD4) antagonists. In the phenyl series, N-[3-(2-quinolinylmethoxy)phenyl]-trifluoromethanesulfonamide (Wy-48,252, 16) was the most potent inhibitor of LTD4-induced bronchoconstriction in the guinea pig. With an intragastric ID50 of 0.1 mg/kg (2-h pretreatment), 16 was 300 times more potent than LY-171,883. Compound 16 also intragastrically inhibited ovalbumin-induced bronchoconstriction in the guinea pig with an ID50 of 0.6 mg/kg. In vitro against LTD4-induced contraction of isolated guinea pig trachea pretreated with indomethacin and L-cysteine, 16 produced a pKB value of 7.7. In the rat PMN assay 16 inhibited both 5-lipoxygenase and cyclooxygenase (IC50's = 4.6 and 3.3 microM). In the naphthyl series, N-[7-(2-quinolinylmethoxy)-2-naphthyl]trifluoromethanesulfonamide (Wy-48,090, 47) in addition to potent LTD4 antagonist activity (on isolated guinea pig trachea 47 had a pKB value of 7.04) also had antiinflammatory activity (63% inhibition at 50 mg/kg in the rat carrageenan paw edema assay and 34% inhibition of TPA-induced inflammation at 1 mg/ear in the mouse ear edema model). Perhaps the antiinflammatory activity of 47 was due to its additional activity of inhibiting both 5-lipoxygenase and cyclooxygenase enzymes (IC50's = 0.23 and 11.9 microM, respectively, in rat PMN).

  DOI：

  10.1021/jm00126a006

文献信息

• Heterocyclic sulphonamides
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0232954A2

  公开（公告）日：1987-08-19

  These are disclosed compounds of the formula wherein X is W is -O-, -S- when n = 0, or W is when n = 1, and the dotted line represents an optional double bond; Y is - CH2O - , - OCH2- , - CH2S, - SCH2- , n is 0 or 1; each R1 is independently hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, halo, trifluoromethyl, cyano or nitro; RZ is hydrogen or lower alkyl; R3 is lower alkyl, perfluoroloweralkyl or perfluorophenyl, with the proviso that when n = 0, R3 is other than lower alkyl; each R4 is independently hydrogen or lower alkyl; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, and in antithrombotic therapy.

  这些化合物的公开式为 其中 X 是 W是-O-、-S- 当 n = 0 时，或 W 是 当 n = 1 时，虚线代表任选双键；Y 是 - CH2O - , - OCH2- , - CH2S, - SCH2- 、 n 是 0 或 1；每个 R1 独立地是氢、低级烷基、低级烷氧基、低级烷酰基、卤代、三氟甲基、氰基或硝基；RZ 是氢或低级烷基；R3 是低级烷基、全氟低级烷基或全氟苯基，但当 n = 0 时，R3 不是低级烷基；每个 R4 独立地为氢或低级烷基；及其药学上可接受的盐，以及它们在治疗白三烯介导的鼻支气管阻塞性气道疾病（如过敏性鼻炎、过敏性支气管哮喘等）和抗血栓治疗中的用途。
• MUSSER, JOHN H.;KREFT, ANTHONY F.;BENDER, REINHOLD H. W.;KUBRAK, DENNIS M+, J. MED. CHEM., 32,(1989) N, C. 1176-1183
  作者：MUSSER, JOHN H.、KREFT, ANTHONY F.、BENDER, REINHOLD H. W.、KUBRAK, DENNIS M+

  DOI：——

  日期：——
• US4675405A
  申请人：——

  公开号：US4675405A

  公开（公告）日：1987-06-23
• N-[(Arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene d4 antagonists of novel structure
  作者：John H. Musser、Anthony F. Kreft、Reinhold H. W. Bender、Dennis M. Kubrak、Richard P. Carlson、Joseph Chang、James M. Hand

  DOI：10.1021/jm00126a006

  日期：1989.6

  Two series of compounds, N-[(arylmethoxy)phenyl] sulfonamides and N-[(arylmethoxy)naphthyl] sulfonamides, were prepared as leukotriene D4 (LTD4) antagonists. In the phenyl series, N-[3-(2-quinolinylmethoxy)phenyl]-trifluoromethanesulfonamide (Wy-48,252, 16) was the most potent inhibitor of LTD4-induced bronchoconstriction in the guinea pig. With an intragastric ID50 of 0.1 mg/kg (2-h pretreatment), 16 was 300 times more potent than LY-171,883. Compound 16 also intragastrically inhibited ovalbumin-induced bronchoconstriction in the guinea pig with an ID50 of 0.6 mg/kg. In vitro against LTD4-induced contraction of isolated guinea pig trachea pretreated with indomethacin and L-cysteine, 16 produced a pKB value of 7.7. In the rat PMN assay 16 inhibited both 5-lipoxygenase and cyclooxygenase (IC50's = 4.6 and 3.3 microM). In the naphthyl series, N-[7-(2-quinolinylmethoxy)-2-naphthyl]trifluoromethanesulfonamide (Wy-48,090, 47) in addition to potent LTD4 antagonist activity (on isolated guinea pig trachea 47 had a pKB value of 7.04) also had antiinflammatory activity (63% inhibition at 50 mg/kg in the rat carrageenan paw edema assay and 34% inhibition of TPA-induced inflammation at 1 mg/ear in the mouse ear edema model). Perhaps the antiinflammatory activity of 47 was due to its additional activity of inhibiting both 5-lipoxygenase and cyclooxygenase enzymes (IC50's = 0.23 and 11.9 microM, respectively, in rat PMN).